### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### FORM 10-Q

#### (Mark One)

b Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2013

or

o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from \_\_\_\_\_\_ to \_\_\_\_\_

Commission file number 0-21615

PRESSURE BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter)

Massachusetts (State or Other Jurisdiction of Incorporation or Organization) 04-2652826 (I.R.S. Employer Identification No.)

14 Norfolk Avenue South Easton, Massachusetts (Address of Principal Executive Offices)

02375 (Zip Code)

(508) 230-1828

(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. b Yes o No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). b Yes o No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting

## Edgar Filing: PRESSURE BIOSCIENCES INC - Form 10-Q

company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o Accelerated filer o

Non-accelerated filer o Smaller reporting company þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). o Yes b No

The number of shares outstanding of the Issuer's Common Stock as of May 15, 2013 was 11,449,267.

# TABLE OF CONTENTS

# PART I - FINANCIAL INFORMATION

<u>Item 1.</u>	Financial Statements (Unaudited)	3
	Condensed Consolidated Balance Sheets as of March 31, 2013 and	
	December 31, 2012	3
	Condensed Consolidated Statements of Operations for the Three	
	Months Ended March 31, 2013 and 2012	4
	Condensed Consolidated Statements of Cash Flows for the Three	
	Months Ended March 31, 2013 and 2012	5
	Notes to Condensed Consolidated Financial Statements	6
	Management's Discussion and Analysis of Financial Condition and	
<u>Item 2.</u>	Results of Operations	23
<u>Item 3.</u>	Quantitative and Qualitative Disclosures About Market Risk	27
<u>Item 4.</u>	Controls and Procedures	27
PART II - OTHER INFORMATIC	<u>DN</u>	
<u>Item 1a.</u>	Risk Factors	28
<u>Item 2.</u>	Unregistered Sales of Equity Securities and Use of Proceeds	28
<u>Item 6.</u>	<u>Exhibits</u>	29
-		
2		

Page

## PART I. FINANCIAL INFORMATION

## ITEM 1. FINANCIAL STATEMENTS

# PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS

ASSETS	March 31, 2013 (Unaudited)	December 31, 2012 (Audited)
CURRENT ASSETS		
Cash and cash equivalents	\$167,910	\$1,461
Accounts receivable	278,020	216,265
Inventories, net of \$50,000 reserve at March 31, 2013 and December 31, 2012	890,853	923,362
Prepaid income taxes	7,381	